Dr. Janjigian Discusses Afatinib and Cetuximab for Patients With EGFR-Mutant Lung Cancer
August 4th 2014
Yelena Y. Janjigian, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses results of an early-phase study looking at afatinib and cetuximab for patients with EGFR-mutant lung cancer.